High-rate breakthrough cancer pain and tumour characteristics – literature review and case series

Arturo Cuomo, Anastasios Boutis, Francesca Colonese, Davide Nocerino

Article Type

Review

Published

The aim of this narrative review is to explore the relationship between high-rate breakthrough cancer pain, which strongly impacts health-related quality of life and tumour characteristics, in the face of novel approaches that should provide guidance for future clinical practice.

Read more

HR+/HER2– de novo metastatic breast cancer:
a true peculiar entity?

Rosalba Torrisi, Flavia Jacobs, Chiara Miggiano, Rita De Sanctis, Armando Santoro

Article Type

Review

Published

This is a critical narrative review focusing on HR+/human epidermal growth factor receptor 2-negative (HER2–) de novo metastatic breast cancer in terms of genomic, biological, pathological, and clinical features and outcomes after systemic and locoregional treatments, outlining differences with recurrent metastatic breast cancer.

Read more

Relationship between breakthrough cancer pain, background cancer pain and analgesic treatment – case series and review of the literature

Chrysanthi Batistaki, Michal Graczyk, Marcin Janecki, Agata Anna Lewandowska, Rita Moutinho, Kiriaki Vagdatli

Article Type

Review

Published

The aim of this paper is to provide healthcare professionals involved in cancer pain management with a review of the relevant literature on the relationship between background cancer pain and breakthrough cancer
pain.

Read more

Deferiprone, an iron chelator, alleviates platelet hyperactivity in patients with β-thalassaemia/HbE

Ngan Thi Tran, Pranee Sutcharitchan, Jindaporn Janprasit, Ponlapat Rojnuckarin, Noppawan Phumala Morales, Rataya Luechapudiporn

Article Type

Original Research

Published

This study was designed to evaluate the antiplatelet effect of deferiprone in patients with transfusion-dependent β-thalassaemia/Hb E at the dose of iron-chelation therapy. The results may provide a mechanistic insight in antiplatelet effects and support the benefit of deferiprone in the prevention of thrombotic events in β-thalassaemia.

Read more

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer

Biagio Ricciuti, Alessia Mira, Elisa Andrini, Pietro Scaparone, Sandra Vietti Michelina, Federica Pecci, Luca Cantini, Andrea De Giglio, Giuseppe Lamberti, Chiara Ambrogio, Giulio Metro

Article Type

Review

Published

The authors review the current treatment landscape for patients with advanced non-small-cell lung cancers harbouring a KRAS G12C mutation, including PD-(L) 1-based therapies and direct KRAS inhibitors as well as sequential treatment options.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.